EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

TEMPORARY REMOVAL: Use of an Integrative Genomics Approach to Identify Metastatic NSCLC Patients Benefiting From the Addition of Chemotherapy to Immune Checkpoint Inhibitors

Mark Klein, Drew Watson, Michael Castro, Shweta Kapoor, Prashant Ramachandran Nair, Swaminathan Rajagopalan, Haixia Qin, Megan Glaser, Anders Westanmo, Deepak Anil Lala, Ansu Kumar, Jyoti Chauhan und 12 weitere

Clinical Lung Cancer · 2025

DOI: 10.1016/j.cllc.2025.10.021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lung Cancer, 2025. Verfasst von Mark Klein und 23 weiteren Autor:innen. Beteiligte Einrichtung: Primary and Specialty Integrated Care Community, Minneapolis VA Health Care System, Minneapolis, MN; Department of Medicine, University of Minnesota,…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Immune Checkpoint Inhibitors, Lung Neoplasms, Genomics. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Office of Research and Development, US Department of Veterans Affairs.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Not all non-small cell lung cancer (NSCLC) patients benefit from chemotherapy when added to immune checkpoint inhibitors (ICI). We used comprehensive genomic profiling coupled with a computational biology model (Cellworks) to create an algorithm to identify patients who may benefit from adding chemotherapy to ICI (ICI+C). PATIENTS AND METHODS: The algorithm (Therapy Response Index, or TRI) was trained in a retrospective cohort of 553 NSCLC patients from the U.S. Veteran's Health Administration (VHA) system who received comprehensive genomic profiling. The TRI, computational model and clinical threshold were locked and validated in 710 advanced NSCLC front-line patients receiving either ICI or ICI+C, obtained from the Flatiron Health-Foundation Medicine NSCLC clinico-genomic database. RESULTS: The classifier was significantly associated with OS in a multivariate analysis. (LR P = .0355). Patients with a low TRI (TRI ≤ 32) received an estimated incremental benefit in median OS of ∼ 3 months with ICI+C (LR P = .04). In contrast, patients with a high TRI (TRI > 32) showed no improvement in median OS when receiving ICI+C. A statistical test of interaction between TRI and chemotherapy met prespecified criteria of P < .25 (LR P = .1361), suggesting that TRI may be predictive of chemotherapy benefit. CONCLUSIONS: TRI was predictive of OS and incremental chemotherapy benefit in patients with NSCLC receiving ICI or ICI+C. These results support the use of the classifier to identify patients who may benefit from ICI+C and those unlikely to respond to ICI alone, independent of PD-L1 levels.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungImmune Checkpoint InhibitorsLung NeoplasmsGenomicsAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleRetrospective StudiesAgedMiddle AgedPrognosisAlgorithmsBiomarkers, Tumor

Stichwörter der Autor:innen

BiomarkerBiosimulationEfficacyImmunotherapyPredictive biomarker

Substanzen

Immune Checkpoint InhibitorsBiomarkers, Tumor

Autor:innen und Institutionen

  • Primary and Specialty Integrated Care Community, Minneapolis VA Health Care System, Minneapolis, MN; Department of Medicine, University of Minnesota, Minneapolis, MN.
  • Department of Research and Development, Cellworks Group, Inc, South San Francisco, CA.
  • Department of Medicine, University of Minnesota, Minneapolis, MN.
  • Primary and Specialty Integrated Care Community, Minneapolis VA Health Care System, Minneapolis, MN.
  • Department of Research and Development, Cellworks Group, Inc, South San Francisco, CA. Electronic address: jwingrove@cellworksgroup.com.
  • Deparment of Medicine-Medical Oncology, Univerisity of Colorado, Boulder, CO.

Förderung

  • Office of Research and Development
  • US Department of Veterans Affairs

Zitieren

APA

Klein, M., Watson, D., Castro, M., Kapoor, S., Nair, P. R., Rajagopalan, S., Qin, H., Glaser, M., Westanmo, A., Lala, D. A., Kumar, A., Chauhan, J., G, P., Ullal, Y. S., Kulkarni, S., Narvekar, Y., Ghosh, A., Tyagi, A., Patil, M., …, & Ganti, A. K. (2025). TEMPORARY REMOVAL: Use of an Integrative Genomics Approach to Identify Metastatic NSCLC Patients Benefiting From the Addition of Chemotherapy to Immune Checkpoint Inhibitors. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2025.10.021

Vancouver

Klein M, Watson D, Castro M, Kapoor S, Nair PR, Rajagopalan S, et al. TEMPORARY REMOVAL: Use of an Integrative Genomics Approach to Identify Metastatic NSCLC Patients Benefiting From the Addition of Chemotherapy to Immune Checkpoint Inhibitors. Clinical Lung Cancer. 2025. doi:10.1016/j.cllc.2025.10.021

BibTeX
@article{Klein2025,
  author = {Klein, Mark and Watson, Drew and Castro, Michael and Kapoor, Shweta and Nair, Prashant Ramachandran and Rajagopalan, Swaminathan and Qin, Haixia and Glaser, Megan and Westanmo, Anders and Lala, Deepak Anil and Kumar, Ansu and Chauhan, Jyoti and G, Poornachandra and Ullal, Yashaswini S and Kulkarni, Shruthi and Narvekar, Yugandhara and Ghosh, Adity and Tyagi, Anuj and Patil, Mamatha and Macpherson, Michele Dundas and Wingrove, James Alan and Patil, Tejas and Aggarwal, Charu and Ganti, Apar Kishor},
  title = {TEMPORARY REMOVAL: Use of an Integrative Genomics Approach to Identify Metastatic NSCLC Patients Benefiting From the Addition of Chemotherapy to Immune Checkpoint Inhibitors},
  journal = {Clinical Lung Cancer},
  year = {2025},
  doi = {10.1016/j.cllc.2025.10.021}
}
Kostenlos starten →